Becton-Dickinson Medical Device Company Intelligence Report

Date: May 31, 2013
Pages: 28
US$ 515.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Becton-Dickinson Medical Device Company Intelligence Report
Becton, Dickinson and Company (BD) is engaged principally in the manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, industry and the general public. Its operations consist of three worldwide business segments: BD Medical, BD Diagnostics and BD Biosciences.

BD Medical produces a portfolio of medical devices that are used in a wide range of healthcare settings. They include safety-engineered injection, infusion and surgery products. BD Medical’s principal product lines include needles, syringes and intravenous (IV) catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self injection of insulin and other drugs used in the treatment of diabetes; prefillable drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations; regional anaesthesia needles and trays; sharps disposal containers; and home healthcare products. The primary markets served by BD Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; public health agencies; pharmaceutical companies; and healthcare workers.

BD Diagnostics provides products for the collection and transport of diagnostic specimens and instrumentation for analysis across a broad range of infectious disease testing, including healthcare-associated infections (HAIs). BD Diagnostics’ principal products and services include integrated systems for specimen collection; safety-engineered collection products and systems; plated media; automated blood culturing systems; molecular testing systems for sexually-transmitted diseases and HAIs; micro-organism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screenings; and rapid diagnostic assays. BD Diagnostics serves hospitals, laboratories and clinics; reference laboratories; blood banks; healthcare workers; patients; physicians’ office practices; and industrial microbiology laboratories.

BD Biosciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. BD Biosciences’ principal product lines include fluorescence activated cell sorters and analysers; cell imaging systems, monoclonal antibodies and kits for performing cell analysis; reagent systems for life sciences research; tools to aid in drug discovery and growth of tissue and cells; cell culture media supplements for biopharmaceutical manufacturing; and diagnostic assays. The primary markets served by BD Biosciences are research and clinical laboratories; hospitals and transplant centres; blood banks; and biotechnology and pharmaceutical companies.

BD’s products are manufactured and sold worldwide. The company has manufacturing operations outside the US in Brazil, Canada, China, France, Germany, Hungary, India, Ireland, Japan, Mexico, Pakistan, Singapore, South Korea, Spain, Sweden and the UK.

The BD Medical Device Company Report provides a full review of the company's medical device activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures and litigation. Sections are also included on products, corporate strategy and R&D.

Whatever your interest or involvement, evaluating the performance, success, failures and developments of medical companies is critical. Espicom’s Medical Device Company Reports have been regularly published for over 20 years, and these critically acclaimed and respected management reports provide a complete review of leading players in the field.

Key Benefits
  • Evaluate competitive threats
  • Maximise product and market opportunities
  • Identify collaborators and strategic partners
  • Understand the operating market environment
  • Benchmark your performance against competitors
Coverage Overview
  • Key contact information
  • Introduction to BD and its current activities
  • Summary of its financial performance
  • Key recent events in an “at a glance” format
Strategic Focus

The company’s aims and its areas of focus

Financial Review
  • Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
  • Table providing in-depth five-year financial analysis
  • Employee data, including breakdown by company division and geographic location
Product Overview
  • Core product areas, key brands, product approvals and launches
  • Identifies the company’s major competitors
Research and Development
  • How much has been invested in R&D?
  • Where is the research based?
  • What alliances and agreements does BD have and with whom?
Manufacturing and Distribution
  • Identifying the company’s manufacturing locations
  • Sales and marketing facilities
  • With whom has BD reached agreements and what do they involve?
Key contracts awarded

Mergers and Acquisitions

Minority Investments



Key Corporate Events

The report was produced as part of Medical Device Companies Analysis (MDCA).


Espicom View


Fiscal Year 2012 Financial Results
  BD Medical
  BD Diagnostics
  Biosciences Segment
Five-Year Financial Data


BD Medical
  Medical Surgical Systems
  Pharmaceutical Systems
  Diabetes Care
  BD Medical Product Updates
BD Diagnostics
  Preanalytical Systems
  Diagnostic Systems
  BD Diagnostics – TriPath Products
  BD Diagnostics – Infectious Disease
  BD Diagnostic Product Updates


Research Establishments
R&D Expenditure
R&D Projects
  BD Max Development
  Juvenile Diabetes Research Foundation






Cato Software Solutions
Safety Syringes
Kiestra Lab Automation
Carmel Pharma


Discovery Labware Unit


Retractable Technologies



Recent Key Events
Fiscal Year 2012 Financial Results
BD - Annual Financial Results, 2008-2012
BD - Annual Revenues by Business Segment and Geographic Area, 2009-2012
BD - Annual Revenues and Operating Income by Business Segment, 2008-2012
BD Medical - Annual Revenue by Unit and Geographic Area, 2009-2012
BD Diagnostics - Annual Revenue by Unit and Geographic Area, 2009-2012
BD Biosciences - Annual Revenue by Unit and Geographic Area, 2009-2012
BD – Five-Year Financial Summary
BD Employees, 2008-2012
Medical Surgical Systems Key Product Areas
Preanalytical Systems Key Product Areas
BD Diagnostics – Planned Product Launches
BD - R&D Expenses, 2008-2012
Agreements Summary
Mergers and Acquisitions Summary


BD - Annual Sales and Operating Income, 2008-2012
BD - Annual Revenues by Geographic Area, 2009-2012
BD- Annual Sales by Business Segment, 2008-2012
BD Medical - Annual Sales by Product Area, 2009-2012
BD Diagnostics - Annual Sales by Product Area, 2009-2012
Skip to top

Sorin Medical Device Company Intelligence Report US$ 515.00 Jun, 2012 · 42 pages
Smith Medical Device Company Intelligence Report US$ 515.00 Mar, 2013 · 40 pages
ConvaTec Medical Device Company Intelligence Report US$ 515.00 Mar, 2012 · 34 pages
Fresenius Medical Device Company Intelligence Report US$ 515.00 Apr, 2013 · 42 pages

Ask Your Question

Becton-Dickinson Medical Device Company Intelligence Report
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: